Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Cash flows from operating activities:
Net income (loss)	$ 21,951,795	$ (393,401)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on related party investment – TNF	(21,395,734)	0
Stock-based compensation	341,832	0
Change in fair value of warrant liability	(3,913,000)	(2,623,000)
Change in fair value of derivative liability	(2,184,000)	1,299,000
Change in fair value of convertible note receivable	(680,000)	0
Change in fair value of warrant asset – Femasys	1,234,000	0
Change in fair value of investment – TNF	3,540,734	0
Change in assets and liabilities:
Decrease in prepaid expenses and other current assets	(233,413)	(215,508)
Increase (decrease) in accounts payable	(40,775)	(2,118)
Increase (decrease) in accrued expenses	(49,471)	293,632
Net cash provided by (used in) operating activities	(1,428,032)	(1,641,395)
Cash flows from investing activities:
Investment in preferred stock and warrants	(7,000,000)	0
Net cash used in investing activities	(7,000,000)	0
Cash flows from financing activities:
Repurchase of common stock	(2,145,708)	(26,622,277)
Proceeds from issuance of preferred stock	0	33,650,075
Redemption of preferred stock	(18,766,416)	0
Proceeds from warrant exercise	0	70
Net cash provided by (used in) financing activities	(20,912,124)	7,027,868
Effect of currency rate exchange on cash and cash equivalents	244	(1,140)
Net increase (decrease) in cash and cash equivalents	(29,339,912)	5,385,333
Cash and cash equivalents at beginning of the period	50,179,968	68,039,936
Cash and cash equivalents at end of the period	20,840,056	73,425,269
Supplemental disclosure of cash flows information:
Cash paid during the periods for income taxes	0	1,600
Supplemental disclosure of cash flows information:
Non-cash derivative liability at initial fair value	0	2,770,000
Non-cash warrant liability at initial fair value	0	14,127,000
Reclassification of Series B Convertible Preferred Stock and dividends to current liability	16,190,179	4,095,271
Accretion of discounts to redemption value of Series B Preferred Stock	3,193,404	7,733,130
Excise tax accrued on repurchase of common stock	$ 21,457	$ 266,223